NewAmsterdam Pharma Co N.V. — Form SCHEDULE 13D/A
Filed September 22, 2026 · analyzed by the Ownership Agent
SCHEDULE 13D/A
— Neutral
significance 28/100
What the filing says
Three Flaxman-affiliated entities (FLSPF, FLS XI, FLS XII) purchased NewAmsterdam ordinary shares during September 8–18, 2026. Total: ~876,000 shares across all three entities at weighted average prices ranging from $21.09 to $25.20 per share, totaling approximately $19.2M in aggregate capital deployed. Purchases occurred in coordinated tranches across multiple days at varying price points.
Why this rating
Share purchases by related parties are routine 13D disclosure; ~1.5% of market cap deployed over 60 days is ordinary portfolio activity, not material to business trajectory.
See more from September 22, 2026.
EDGAR·FLOW summarizes public SEC EDGAR filings with automated analysis. Materiality scores and stock-impact predictions are algorithmically generated and are not investment advice. Always verify against the source filing on SEC.gov.